Form 4: Foghorn Therapeutics Director Scott Biller Acquires 25,000 Stock Options

Foghorn Therapeutics Inc. Director Scott Biller has acquired 25,000 stock options at an exercise price of $4.79, exercisable from June 17, 2026, and expiring on June 16, 2035.

Summary

• Scott Biller, a Director of Foghorn Therapeutics Inc. (FHTX), reported the acquisition of derivative securities.
• The transaction involved 25,000 stock options, granting the right to buy common stock.
• The exercise price for these options is $4.79 per share.
• The options were acquired on June 17, 2025.
• These options become exercisable on June 17, 2026, and have an expiration date of June 16, 2035.
• Following this transaction, Scott Biller beneficially owns 25,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The acquisition of stock options by a director is generally viewed as a positive signal, indicating insider confidence in the company's future prospects. However, as a routine compliance filing, it does not contain extensive positive or negative operational details.

Positives

• The acquisition of stock options by a director can signal confidence in the company's future performance and long-term value, aligning management's interests with shareholders.

Future Outlook

The document, an SEC Form 4, reports a past transaction and does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically the acquisition of stock options by a director. It does not provide information on broader industry trends or competitive landscape, but rather reflects an individual's equity compensation and potential confidence in the company within the biotechnology or pharmaceutical sector.

Comparison to Industry Standards

• This document is a standard SEC Form 4 filing, which is a mandatory disclosure for insiders reporting changes in beneficial ownership. The structure and content align with regulatory requirements for such filings across all industries, including the biotechnology sector where Foghorn Therapeutics operates.
• The grant of stock options to directors is a common form of equity compensation in publicly traded companies, particularly in growth-oriented sectors like biotech, aiming to align director incentives with long-term shareholder value creation. Specific comparable companies or projects are not mentioned in this filing.

Related Party Transactions

• The acquisition of 25,000 stock options by Scott Biller, a Director of Foghorn Therapeutics Inc., constitutes a related party transaction as it involves an equity award from the company to an insider.

Stakeholder Impact

• Shareholders: The acquisition of options by a director can be interpreted as a positive signal of confidence in the company's future, potentially influencing investor sentiment.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• The reporting person, Scott Biller, may choose to exercise these options at any time between June 17, 2026, and June 16, 2035, assuming the stock price is above the exercise price of $4.79.

Key Dates

Keywords

Foghorn Therapeutics, FHTX, Scott Biller, Stock Options, Insider Trading, SEC Form 4, Beneficial Ownership, Director, Equity Compensation